ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SH\$\(\frac{1}{10}\)/50/SB/08a (05-07) Approved for use through 11/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10587371	
INFORMATION BIOCH COURT	Filing Date		2006-07-26	
INFORMATION DISCLOSURE	First Named Inventor	Ho St	ing CHO	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1646	
(Not for Submission under or of it 1.33)	Examiner Name	Bruce D. HISSONG		
	Attorney Docket Number		AMBX-0028.00US	
	•		•	

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	6638500	B1	2003-10)-28	El-Tayar Nabil	et al.				
	2	6608183	B1	2003-08	3-19	George Cox, II	II				
If you wish	n to a	⊥ dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.	l	Add		
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	Name of Patentee or Applic of cited Document			Releva		Lines where les or Relev	
	1	20030082575	A1	2003-05	5-01	Schultz et al.					
lf you wisl		ldd additional U.S. Publi	shed Ap	l plication	n citatio	l n information p	olease click the Add	l d buttor	Add		
			•	FOREIG	ON PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document	e or	where Rele	or Relevant	T5
	1	EP 1219636	EP		A2	2002-07-03	Dreambiogen Co. L	.td.			
lf you wisl	n to ac	│ dd additional Foreign P	Latent Do	cument	L citation	information pl	lease click the Add	button	Add		
						RATURE DO			Remove		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SHS/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10587371		
Filing Date		2006-07-26		
First Named Inventor Ho Su		ing CHO		
Art Unit		1646		
Examiner Name	Bruce D. HISSONG			
Attorney Docket Number		AMBX-0028.00US		

	""" (hook magazine journal serial symnosium catalog etc) date nages(s) volume-issue number(s)					
	1	Dieters et al., "Adding Amino Acids with Novel Reactive Chem. Soc., October 1, 2003, 125(39):11782-11783.	vity to the Genetic Code of Saccharomyces	s Cerevisiae", J. Am.		
	2	E.A. Cornish, "Probing Protein Structure and Function 1995 34:621-633.	with Expanded Genetic Code", Angew. Cl	nem. Int. Ed. Eng,		
	3	Dieters et al., "Site-Specific PEGylation of Proteins Co December 6, 2004, 14(23):5743-5745.	ontaining Unnatural Amino Acids", Bioorg. (& Med. Chem. Letters,		
you wish	to ac	dd additional non-patent literature document citatio	on information please click the Add bu	ton Add		
		EXAMINER S	SIGNATURE			
xaminer (Signa	ature /Shulamith Shafer/	Date Considered	02/15/2009		
		nitial if reference considered, whether or not citatio conformance and not considered. Include copy o		_		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10587371
Filing Date		2006-07-26
First Named Inventor Ho Su		ung CHO
Art Unit		1646
Examiner Name Bruce		D. HISSONG
Attorney Docket Number		AMBX-0028.00US

	CERTIFICATION STATEMENT								
Plea	Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):								
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).								
OR	OR								
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).								
	See attached ce	ertification statement.							
	Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.								
×	X None								
SIGNATURE A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.									
Sigr	nature	/John W. Wallen/	Date (YYYY-MM-DD)	2008-10-29					
Nan	ne/Print	John W. Wallen, III	Registration Number	35403					
		,							

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a
 court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
 negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.